Watch the latest episode in the Pioneering Pathways interactive series to learn more about one mechanism of action that is being investigated to help address the unmet needs of patients living with post-traumatic stress disorder.
Post-traumatic stress disorder (PTSD) is a common psychiatric condition affecting approximately 10 million Americans that can result from actual or threatened traumatic events and experiences. Learn more about the prevalence of this complex psychiatric condition and Jazz’s efforts to address the significant unmet need for patients.
Dravet syndrome is a rare, severe, lifelong form of treatment-resistant epilepsy that typically begins in the first year of life.
The onset of cardiovascular events and risk factors is high among those living with narcolepsy, even among patients who do not have a history of these cardiovascular conditions. Learn more about the key findings of the CV-BOND study, recently presented by Rami H. Ben-Joseph, Ph.D., head of big data real world evidence at Jazz.
Thank you! We'll get back to you shortly.
Please select and enter the required fields on the form below. We need this information to process your request and to take necessary steps to verify your identity.
We will contact you if we need any additional information
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.